basal insulin plus glp 1 FDA Approves Awiqli® — The First Once-Weekly for Type 2 Diabetes, Novo Nordisk announced that on March 26, 2026, the U.S. FDA approved Awiqli® (insulin icodec-abae) 700 units/mL, the Glucagon-Like Peptide-1 Based Therapies: A
Pay in 4 interest-free payments of $6.30 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5






















